Silence Therapeutics PLCOTC Pink - Current Information:SLNCF
- LAST PRICE7.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 7.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Apr 30, 2024
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2(nd) Annual BioConnect Investor Conference, from 8:30AM ET on Tuesday Apr 30, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 30, 2024 by Dow Jones
Apr 29, 2024
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors, from 8:30AM ET on Monday Apr 29, 2024 by Dow Jones
8:30AM ET on Monday Apr 29, 2024 by Dow Jones
Apr 22, 2024
DJ Silence Therapeutics Is Maintained at Overweight by Morgan Stanley, from 1:39PM ET on Monday Apr 22, 2024 by Dow Jones
1:39PM ET on Monday Apr 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Silence Therapeutics PLC | 986.3M | -14.3x | --- |
4D Molecular Therapeutics Inc | 1.3B | -10.0x | --- |
Pharvaris NV | 1.2B | -7.9x | --- |
Abcellera Biologics Inc | 1.1B | -7.6x | --- |
Gyre Therapeutics Inc | 1.3B | -0.7x | --- |
Verona Pharma PLC | 1.2B | -18.8x | --- |
Company Information
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Contact Information
- Headquarters
- 72 Hammersmith RoadLONDON, United Kingdom W14 8TH
- Phone
- 203-457-6900
- Fax
- 795-731-8494
Executives
- Non-Executive Chairman of the Board
- Iain Ross
- President, Chief Executive Officer, Executive Director
- Craig Tooman
- Executive Director, Head of Research and Development, Chief Medical Officer
- Giles Campion
- Company Secretary
- Sarah Murphy
- Non-Executive Director
- Michael Davidson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $986.3M |
|---|---|
Revenue (TTM) | $35.1M |
Shares Outstanding | 46.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.53 |
EPS | $-0.49 |
Book Value | $0.26 |
P/E Ratio | -14.3x |
Price/Sales (TTM) | 28.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -168.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
